Syncordia Technologies and Healthcare Solutions, Corp. Announces Collateral Agent Demand Letter Notice of Intention to Enforce Security
TORONTO, April 5, 2018 /CNW/ - Syncordia Technologies and Healthcare Solutions, Corp. (TSXV: SYN) (the "Company") has been operating under a forbearance arrangement with its secured lender since July 2017. Efforts to sell the business or refinance have not succeeded. The Company has now received: (i) a demand letter for immediate repayment of its Secured Notes issued on November 5th, 2014 with a current outstanding balance of approximately $14,262,082.76; and (ii) a notice of intention to enforce security pursuant to section 244(1) of the Bankruptcy and Insolvency Act (Canada) dated April 4, 2018. While the collateral agent would otherwise be required to wait 10 days to enforce such security, the Company has consented to the waiver of such period. The secured lender has advised that it intends to seek the appointment of Grant Thornton Ltd. as receiver and manager.
The Company received the resignation of each of the Company's Directors dated today.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Syncordia Technologies and Healthcare Solutions, Corp.
eBlu Solutions, a leading provider of innovative technology solutions for the specialty healthcare industry, is pleased to announce the addition of Doug Lawrence to the Executive Leadership team in the role of Chief Revenue Officer.
"We're not just...
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL?HF,...
Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at...
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology,...
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...